A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 22 Oct 2018 Results published in a BerGenBio media release.
- 22 Oct 2018 According to a BerGenBio media release, predictive and pharmacodynamic Biomarkers results presented at the ESMO 2018 Congress.
- 28 Sep 2018 The trial has been completed in Spain (End Date;2018-08-20).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History